Light Science Technologies achieves positive EBITDA with expanding margins. WATCH the interview here.

Less Ads, More Data, More Tools Register for FREE

Latest trial over Zantac cancer claims called off as plaintiff drops case

Mon, 10th Jun 2024 22:49

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

GSK said in a statement that it did not settle with the woman, Eugenia Kasza. A lawyer for Kasza did not immediately respond to a request for comment.

Kasza's case would have been the second over Zantac to go to trial, after the first ended last month with a victory for GSK and Boehringer Ingelheim, which also sold Zantac. Another case was dismissed by a judge shortly before a trial was set to begin on May 23.

More than 72,000 lawsuits remain pending over Zantac against companies that sold the drug, which also include Pfizer and Sanofi. Sanofi has settled about 4,000 cases, and the Financial Times reported last month that Pfizer had settled more than 10,000 cases.

A Delaware judge earlier this month ruled that the cases could go forward, rejecting a bid by GSK and other drugmakers to stop plaintiffs from offering expert testimony that the drug can cause cancer. The drugmakers have said they will appeal.

First approved in 1983, Zantac became the world's best selling medicine in 1988 and one of the first to top $1 billion in annual sales. It was originally marketed by a forerunner of GSK and later sold successively to other companies.

In 2019, some manufacturers and pharmacies halted Zantac sales after a chemical called NDMA, which is known to cause cancer, was detected in some pills. Some tests showed that Zantac's active ingredient, ranitidine, could degrade into NDMA over time or when exposed to heat.

The U.S. Food and Drug Administration asked manufacturers to pull the drug off the market in 2020. In the face of mounting lawsuits, the drugmakers have maintained that there is no evidence Zantac exposed users to harmful levels of NDMA.

The companies notched a significant win in 2022, when another judge rejected about 50,000 lawsuits making similar claims that had been consolidated in federal court in Florida. Some plaintiffs are appealing that ruling. (Reporting By Brendan Pierson in New York, Editing by Alexia Garamfalvi and Bill Berkrot)

Related Shares

More News
Today 11:18

GSK moves to new global headquarters in return to central London

(Alliance News) - Pharmaceutical company GSK PLC is set to move its global headquarters back to central London, ending more than two decades at its Br...

8 Jul 2024 09:27

LONDON BROKER RATINGS: UBS cuts GSK; RBC raises Melrose Industries

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

8 Jul 2024 07:48

LONDON BRIEFING: Carlsberg to buy Britvic in GBP3.3 billion deal

(Alliance News) - Stocks in London are called to open lower on Monday, amid political deadlock across the Channel in France.

5 Jul 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts Softcat to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday:

5 Jul 2024 08:33

Citi cuts GSK target price after Arexy disappointment, but stays at 'buy'

(Sharecast News) - Citi has reiterated its 'buy' rating on GSK despite a flurry of disappointing news for the biopharma giant in recent weeks, though ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.